Stockscreener 앱 받기
40.84
1.92%
-0.80
시간 외 거래:
40.94
0.10
+0.24%
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Will Ionis Pharmaceuticals' (IONS) Return to Profitability and Raised Guidance Shift Its Investment Narrative? - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/6/2025 - AInvest
Ionis Pharmaceuticals EVP Geary Richard S sells 10,000 shares at $42.86/share on August 5. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ionis Pharma EVP Schneider sells $408,701 in stock By Investing.com - Investing.com South Africa
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline - openPR.com
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Ionis Pharmaceuticals (IONS): Morgan Stanley Upgrade and Future ProspectsNews and Statistics - IndexBox
Ionis Pharmaceuticals Inc. Stock Lags Behind Sector BenchmarksHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why Morgan Stanley Upgraded This Biotech Stock to a Buy - Yahoo Finance
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
How does Ionis Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Ionis Pharmaceuticals Inc. company’s key revenue driversFree Popular Stock Recommendations - Jammu Links News
What institutional investors are buying Ionis Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Is it the right time to buy Ionis Pharmaceuticals Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve breakthrough profits with expert advice - Jammu Links News
Is Ionis Pharmaceuticals Inc. a growth stock or a value stockMarket-crushing profits - Jammu Links News
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketCapital growth strategies that work - Jammu Links News
What makes Ionis Pharmaceuticals Inc. stock price move sharplyBuild wealth with high-performing stocks - Jammu Links News
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is Ionis Pharmaceuticals Inc. company’s growth strategyUnprecedented profits - Jammu Links News
What catalysts could drive Ionis Pharmaceuticals Inc. stock higher in 2025Invest confidently with professional advice - Jammu Links News
When is Ionis Pharmaceuticals Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
Is Ionis Pharmaceuticals Inc. stock overvalued or undervaluedUnlock powerful market insights for success - Jammu Links News
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastGet professional advice for portfolio optimization - Jammu Links News
What are the latest earnings results for Ionis Pharmaceuticals Inc.Maximize gains with data-driven trading alerts - Jammu Links News
Mixed Analyst Opinions on Healthcare Stocks: Teladoc, Ionis Pharmaceuticals, and Repligen - AInvest
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) - simplywall.st
How does Ionis Pharmaceuticals Inc. generate profit in a changing economyAI Powered Target Finder For Consistent Profits - Jammu Links News
Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS) - MSN
Ionis (IONS) Q2 Revenue Soars 101% - The Globe and Mail
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target t - GuruFocus
UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com
Ionis Pharmaceuticals: Raymond James raises PT to $64, maintains Strong Buy rating. - AInvest
Ionis Pharmaceuticals stock price target raised to $65 from $50 at H.C. Wainwright - Investing.com Canada
Ionis Pharmaceuticals: Q2 Earnings Snapshot - Huron Daily Tribune
Ionis reports second quarter 2025 financial results and highlights progress on key programs - BioSpace
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Ionis Pharmaceuticals shares fall 1.86% after-hours after Morgan Stanley upgrades to Overweight. - AInvest
Morgan Stanley upgrades Ionis Pharmaceuticals stock rating on strong Tryngolza launch - Investing.com Nigeria
1.02%
3.70%
자본화:
|
볼륨(24시간):